Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Gold Leads, Will the Rest Follow?

The natural resource landscape has shifted dramatically since the end of 2018. At the time, we were still nursing our wounds from an unexpectedly vicious 2018 and hoping to avoid a repeat performance in 2019. I did speculate that "we may have already exited the bear mar...

Bad Moon Rising

For those of you that have followed my raves and rants over the years, you are undisputedly aware of all of my biases when it comes to almost everything: bankers, politicians, invasive species, free market suppression, entitled Millennials, and finally, the utility of p...

Speculators remain skeptical of Veeco Instruments (VECO)

Since March 2009, Veeco Instruments Inc. ’s ( NASDAQ: VECO , Stock Forum ) steep ascent has been underlined by its 10-week and 20-week moving averages. These intermediate-term trendlines have contained all of VECO's weekly closes in the intervening months, ...

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...

The Unfolding Soft Patch in S&P 500

Stocks indeed experienced a down day yesterday, and the credit markets say it might not be over just yet. With today's premarket upswing rejected at recent highs, will the bears smell an opportunity? While I continue to think it'll turn out to be a blip on the screen, I have m...

Reigniting the Cannabis Oral Delivery System Marketplace

This podcast is part of our Cannabis Sector CEO interview series, and our mission going forward is to help listeners and investors understand more about investment opportunities in the public marketplace. Stockhouse Media's Dave Jackson was recently joined live with Bra...

Will Repogeddon Make Gold Rally?

One of the most important recent developments in the world of finance was the September liquidity crisis in the U.S. repo market. As a reminder, the repo market is where borrowers borrow cash from lenders against collateral in the form of safe securities such as government bon...

Buzz on the Bullboards: Where volatility meets opportunity

It has been a wild ride for markets on Bay Street and Wall Street this week. Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day. It is reporting season for many companies, and Stockhouse users seem...

Why XOM is close to an ideal option trading candidate

XOM has a hugely active options series, trades in both monthly and weekly expiration series and has bid / ask spreads that are just a few pennies wide. One of the most interesting aspects of options is the myriad opportunities presented for high probability trades for thos...

Natural gas trade trumps gold's comeback

In our report published November 20, 2009, we recommended immediate action be taken regarding gold positions in general and in a particularly profitable, zero premium trade in silver that we had prescribed several weeks prior. In the face of a steadily rising bullion price w...
1 2 3 4 5 6 7 8 9 10 ...